US · PHAR
Pharming Group N.V.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Leiden 2333 CR
- Website
- pharming.com
Price · as of 2024-12-31
$16.98
Market cap 1.14B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $49.80 | +193.29% |
| Intrinsic Value(DCF) | $45.06 | +165.37% |
| Graham-Dodd Method(GD) | $2.70 | -84.1% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $1,073.40 | |||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $12.10 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $10.90 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $3.10 | $20.50 | |||
| 2019 | $4.50 | $16.80 | |||
| 2020 | $13.43 | $43.60 | $96.91 | $5.00 | $10.80 |
| 2021 | $8.52 | $38.89 | $2.16 | $3.60 | $0.50 |
| 2022 | $11.80 | $37.40 | $1.80 | $3.31 | $1.89 |
| 2023 | $11.51 | $52.45 | $1.90 | $2.53 | $0.00 |
| 2024 | $8.05 | $42.57 | $17.62 | $2.70 | $0.00 |
AI valuation
Our deep-learning model estimates Pharming Group N.V.'s (PHAR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $49.80
- Current price
- $16.98
- AI upside
- +193.29%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$45.06
+165.37% upside
Graham-Dodd
$2.70
-84.1% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PHAR | Pharming Group N.V. | $16.98 | 1.14B | +151% | +165% | -84% | — | -55.82 | 2.14 | 1.60 | 25.65 | -260.51 | 2.96 | 88.09% | -2.90% | -3.98% | -3.86% | -5.04% | -1.97% | 0.51 | -0.99 | 3.77 | 2.95 | 3.52 | 2143.00% | 2115.00% | -8619.00% | -0.55% | -0.02 | -1.51% | 0.00% | 0.00% | 11.06% | -48.54 | -161.51 | 1.41 | 1.91 |
| ABUS | Arbutus Biopharma Corpora… | $4.66 | 896.23M | +556% | -71% | — | +345% | -8.79 | 6.31 | 99.56 | -7.21 | — | 6.31 | 100.00% | -1236.74% | -1133.04% | -68.76% | 433.24% | -50.65% | 0.01 | -557.07 | 8.15 | 8.01 | 0.51 | -1364.00% | -6598.00% | -2520.00% | -10.59% | -4.15 | 369.16% | 0.00% | 0.00% | 2.84% | -6.46 | -7.58 | 79.89 | -4.43 |
| BCAX | Bicara Therapeutics Inc. … | $16.78 | 919.24M | — | — | — | — | -13.25 | 1.83 | — | -5.00 | -52.99 | 1.83 | 0.00% | — | — | -19.14% | 1967.97% | -16.93% | 0.00 | — | 27.93 | 27.22 | 5.94 | 2500.00% | — | 6190.00% | -8.31% | -4.16 | 1787.22% | 0.00% | 0.00% | 28.78% | -5.00 | -5.50 | — | 6.99 |
| EYPT | EyePoint Pharmaceuticals,… | $17.56 | 1.45B | +9,195% | -75% | — | — | -3.07 | 1.19 | 9.28 | -0.41 | -11.16 | 1.19 | 91.42% | -337.06% | -302.43% | -43.42% | 403.05% | -33.83% | 0.06 | -10418.14 | 7.81 | 7.57 | 0.60 | 2747.00% | -597.00% | 800187.00% | -32.46% | -2.57 | 360.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 1.21 | -0.07 |
| FTRE | Fortrea Holdings Inc. | $10.72 | 990.53M | +1% | -61% | — | — | -0.98 | 1.71 | 0.35 | -1.05 | -0.50 | -0.95 | 15.63% | -32.04% | -36.21% | -102.41% | -60.19% | -31.33% | 0.12 | -9.55 | 0.98 | 0.84 | 0.13 | 19455.00% | 100.00% | -6279.00% | 9.17% | 0.12 | 6.09% | 0.00% | 0.00% | 123.21% | -0.98 | 9.70 | 0.31 | -0.51 |
| KURA | Kura Oncology, Inc. | $8.73 | 759.66M | — | — | — | — | -3.73 | 1.57 | 12.04 | 0.37 | — | 1.57 | 100.00% | -358.55% | -322.89% | -42.91% | 126.01% | -28.78% | 0.04 | -119.33 | 9.46 | 9.24 | 1.23 | -288.00% | — | -20708.00% | 20.63% | 1.71 | -87.30% | 0.00% | 0.00% | 28.94% | 0.32 | -0.46 | -1.15 | -0.24 |
| MNMD | Mind Medicine (MindMed) I… | $17.47 | 1.32B | — | — | — | — | -4.43 | 1.99 | — | -2.21 | — | 2.17 | — | — | — | -68.01% | 1162.37% | -50.94% | 0.09 | -45.52 | 7.25 | 7.05 | 2.42 | -9385.00% | — | 2294.00% | -16.44% | -2.04 | 885.11% | 0.00% | 0.00% | 34.56% | -2.21 | -2.90 | — | 2.74 |
| PROK | ProKidney Corp. | $2.24 | 277.76M | — | — | — | — | -0.63 | -0.10 | 1352.79 | 1.59 | -7.18 | -0.10 | 100.00% | -241678.95% | -80507.89% | 15.57% | 13.02% | -37.91% | 0.00 | -20408.44 | 10.93 | 9.96 | 0.60 | 877.00% | — | 2542.00% | -151.60% | -3.49 | 11.09% | 0.00% | 0.00% | 38.56% | 1.37 | 1.62 | -3319.00 | -2.64 |
| PVLA | Palvella Therapeutics, In… | $135.02 | 1.6B | — | — | — | — | -3.70 | 1.03 | — | 1.45 | — | 1.03 | 0.00% | — | — | -59.37% | 87.48% | -36.40% | 0.00 | -3.26 | 7.33 | 7.14 | 6.37 | -15312.00% | — | -2089.00% | -16.79% | -0.90 | 67.28% | 0.00% | 0.00% | 118.12% | 1.35 | 1.76 | — | 0.53 |
| SEPN | Septerna, Inc. | $29.02 | 1.3B | +1,403% | -60% | -79% | — | -0.89 | 0.15 | 59.16 | 3.30 | — | 0.15 | 100.00% | -7518.42% | -6678.88% | -37.62% | 815.26% | -24.45% | 0.06 | — | 27.77 | 27.40 | 2.68 | -2504845.00% | 61192.00% | 6724.00% | -109.39% | -5.25 | 706.65% | 0.00% | 0.00% | 215.10% | 3.24 | 3.76 | -243.58 | 1.00 |
| TNGX | Tango Therapeutics, Inc. | $11.14 | 1.23B | +109% | +24,801% | — | — | -1.68 | 1.10 | 5.22 | 0.01 | -16.54 | 1.10 | 100.00% | -346.09% | -309.73% | -57.58% | 436.15% | -36.24% | 0.18 | — | 6.98 | 6.76 | 0.23 | 1019.00% | 1517.00% | 1067.00% | -60.24% | -3.45 | 396.19% | 0.00% | 0.00% | 2.54% | 0.01 | 0.01 | -0.04 | -1.61 |
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
- CEO
- Fabrice Chouraqui
- Employees
- 404
- Beta
- 0.23
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($45.06 ÷ $16.98) − 1 = +165.37% (DCF, example).